Cotempla XR-ODT is a Schedule II controlled substance and is supplied as 8.6mg, 17.3mg, and 25.9mg strength orally-disintegrating tablets in cartons containing 5 blister cards of 6 tablets each.
Two year-long studies assessing safety of dasotraline in children, adolescent and adult ADHD patients found the treatment to be generally well tolerated.
"In two genetically related cohorts at high risk for autism spectrum disorder, reciprocal neuroanatomic abnormalities were found and determined to be associated with cognitive and behavioral impairments," the authors write.
In both studies, more participants on LDX versus placebo were categorized as improved on the Clinical Global Impressions-Improvement starting at week one.
"Importantly, the absolute risk of autism was small, and, hypothetically, if no pregnant women took antidepressants, the number of cases that could potentially be prevented would be small," wrote the authors of the study.
"Immunomodulatory therapy should be considered early, because NSAIDs or a short course of oral corticosteroids may be sufficient for symptom remission in recent-onset cases, whereas those with long-standing symptoms often require more intensive and prolonged immunotherapeutic interventions," the authors write.
Study data showed treatment with Mydayis significantly improved ADHD symptoms, as assessed by the ADHD-RS-IV and the Permanent Product Measure of Performance (PERMP), in both adolescents and adults.
Apotex, Teva, Aurobindo Pharma, and Glenmark are among the first companies to gain approval to market Atomoxetine Capsules in various strengths.
Parents used this information to improve their baby's attention, communication, early language development, and social engagement.
The risk of motor vehicle crash for male patients was reduced by 38% during the months when medication was taken, compared to the months when it was not.
Study data revealed children taking dasotraline 4mg daily had statistically significant and clinically meaningful improvement vs. placebo on the primary endpoint.
Autism spectrum disorder was diagnosed by age 15 in 5.28% of exposed vs. 2.14% of unexposed babies; 12.63% of exposed vs. 5.46% of unexposed babies were diagnosed with ADHD by age 15.
The FDA has warned and/or taken action against a number of companies that have made improper claims about the intended use of their products in relation to treating autism or symptoms of autism.
To examine any potential cognitive improvement, researchers conducted a crossover study of modafinil, methylphenidate, caffeine and placebo.
Researchers reviewed five interventions, included melatonin, drug therapy other than melatonin, alternative therapies (ie, massage, aromatherapy, multivitamin/iron supplementation), behavioral interventions and parent education/education programs.
Through the formation of the international ENIGMA ADHD Working Group, researchers aimed to address weaknesses of previous imaging studies and investigate whether there are structural differences in the brain of those with ADHD.
Licorice consumption during pregnancy has been linked to lower IQ, poorer memory, and attention deficit hyperactivity disorder (ADHD)-type problems in offspring.
For select patients, psychostimulants may be beneficial for treating bulimia nervosa, according to a study of six cases published online January 23 in the Journal of Clinical Pharmacology.
Children who follow a Mediterranean diet may be less likely to have attention-deficit/hyperactivity disorder (ADHD), according to a study published online January 30 in Pediatrics.
A new approach to alter the gut microbiome and virome may be an effective treatment for children with autism spectrum disorder (ASD), according to research published online January 23 in Microbiome.
Researchers sought to determine factors that influence accurate tablet splitting and liquid dosing by patients as compared to healthcare professionals.
Study authors reported evidence of greater opioid receipt among commercially insured patients with a wide range of psychiatric conditions.
The findings, though preliminary, suggest that combined treatment with MAAT and methylphenidate can improve attention, episodic and working memory, and executive functioning following traumatic brain injury.